HealthTech180
  • Home
  • Activities
  • Our Team
  • Contact Us
Select Page

Y-mAbs Initiates Rolling Submission of Biologics License Application to FDA for Naxitamab for Treatment of Neuroblastoma

by admin | Dec 2, 2019 | FDA

Y-mAbs Therapeutics, a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer, announced that it has submitted to the U.S. Food and Drug Administration...
Follow Us
We are a one-stop shop Healthcare Advisory & Consulting boutique and we help businesses with funding, market access, business strategy, distribution.

Categories

Follow Us

Tags

AI Alzheimer antibodies Biosimilar Cancer cardiovascular cell therapy CE Mark clinical trial Diagnostics Digital Health Drug Discovery EpiVax' FDA FDA approval funding fundraising HIV Immunogenicity Immunotherapies INVO Bioscience Licensing M&A medical device microbiome Neuro next-gen sequencing NGS PathAI pathology Pepticom peptides pharma PierianDx RNA robots Shape Therapeutics skin software SurgiMab Therapeutics therapies USA VIrology Virus

Home
Activities
Our Team
Contact Us

         contact@healthtech180.com

Privacy Policy

© 2022 HealthTech180 Advisory S.L.